Similar articles

• Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.

  [No authors listed] [No authors listed] J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173. J Natl Cancer Inst. 2017. PMID: 29117395 No abstract available.
• Perspectives on Cost and Value in Cancer Care.

  Saltz LB. Saltz LB. JAMA Oncol. 2016 Jan;2(1):19-21. doi: 10.1001/jamaoncol.2015.4191. JAMA Oncol. 2016. PMID: 26501848 No abstract available.
• New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.

  Niraula S, Nugent Z. Niraula S, et al. J Natl Compr Canc Netw. 2018 Dec;16(12):1460-1466. doi: 10.6004/jnccn.2018.7084. J Natl Compr Canc Netw. 2018. PMID: 30545993
• Charting the Course: Use of Clinical Pathways to Improve Value in Cancer Care.

  Malin JL. Malin JL. J Clin Oncol. 2020 Feb 1;38(4):367-371. doi: 10.1200/JCO.19.01482. Epub 2019 Dec 5. J Clin Oncol. 2020. PMID: 31804871 Review. No abstract available.
• Economic evaluation of cancer treatments: a review of the methods.

  Brown J. Brown J. Clin Oncol (R Coll Radiol). 1999;11(2):78-83. doi: 10.1053/clon.1999.9018. Clin Oncol (R Coll Radiol). 1999. PMID: 10378631 Review. No abstract available.